Our Company

JNANA IS EXPANDING THE BOUNDARIES OF DRUG DISCOVERY BY UNLOCKING HARD-TO-DRUG TARGETS, INCLUDING SOLUTE CARRIERS (SLCs).
PROPRIETARY CHEMOPROTEOMIC PLATFORM
The engine that propels Jnana’s research is RAPID, a next generation chemoproteomic drug discovery platform that enables us to efficiently identify small molecule modulators for hard-to-drug targets to treat a range of diseases.
PIPELINE AND PARTNERS
Using RAPID, we have built a pipeline of programs to address immune-mediated diseases, oncology and metabolite-dependent diseases, where the metabolite concentration provides a clear translational path to the clinic. We are developing therapeutics internally, as well as with biopharma partners.
EXPERT, COLLABORATIVE TEAM
We are building a company where all employees are empowered to contribute and work together to make breakthrough therapeutics. We are strengthened by our world-renowned scientific founders and the backing of leading life science investors.
Back to Top
 

This links to an external website. Merus is not responsible for any third party content.

Continue